FindTrial
Sign In

Quality of life surveillance in Pariet b.i.d. therapy for refractory reflux esophagitis

Quality of life surveillance in Pariet b.i.d. therapy for refractory reflux esophagitis

Status
Unknown
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1080221998
Enrollment
3750
Registered
2013-01-09
Start date
2013-01-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Reflux Esophagitis

Interventions

investigational material(s) Generic name etc : Pariet INN of investigational material : Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investigational material

Sponsors

Eisai Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Proton pump inhibitor-resistant reflux esophagitis. (Patients who have mucosal breaks (erosions, ulcers) on endoscopy)

Exclusion criteria

Exclusion criteria: -Patients with a history of hypersensitivity to any ingredients of PARIET. -Patients on atazanavir sulfate.

Design outcomes

Primary

MeasureTime frame
-Health related QOL -Symptoms of GERD Number of subjects with improvement based on health related Quality of Life (QOL) questionnaire—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026